Gentian Diagnostics ASFRA:6FK +3.58%73 Dividend Yield % is 1.60% as of Jul. 12, 2026, which is 116% above its 10-year median of 0.74. GuruFocus rates FRA:6FK with a GF Score™ of 73/100 and a GF Value™ of €5.19 (Significantly Undervalued). Among 327 Medical Devices & Instruments companies, Gentian Diagnostics AS ranks worse than 58.41% on this metric.
As of today (2026-07-12), the Trailing Annual Dividend Yield of Gentian Diagnostics AS is 1.60%.
Good Sign:
Gentian Diagnostics AS stock Dividend Yield % is close to 2-year high.
The historical rank and industry rank for Gentian Diagnostics AS's Dividend Yield % or its related term are showing as below:
FRA:6FK'
s Dividend Yield % Range Over the Past 10 Years
Min: 0.63 Med: 0.74 Max: 1.62
Current: 1.6
During the past 13 years, the highest Dividend Yield of Gentian Diagnostics AS was 1.62%. The lowest was 0.63%. And the median was 0.74%.
FRA:6FK's Dividend Yield % is ranked worse than 58.41% of 327
companies
in the Medical Devices & Instruments industry
Industry Median: 1.92
vs FRA:6FK: 1.60
During the past 12 months, Gentian Diagnostics AS's average Dividends Per Share Growth Rate was 50.00% per year.
The growth rate is calculated with least square regression.
For more information regarding to dividend, please check our Dividend Page.
* Please note that "special dividend" is not included in the calculation of dividend per share and related fields.
Gentian Diagnostics AS (FRA:6FK) Dividend Yield % Explanation
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
Gentian Diagnostics AS Dividend Yield % Related Terms
Gentian Diagnostics AS Dividend Yield % Historical Data
* Premium members only.
The historical data trend for Gentian Diagnostics AS's Dividend Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:6FK vs ABT, SYK, MDT: Dividend Yield % Comparison
For the Medical Devices subindustry, Gentian Diagnostics AS's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gentian Diagnostics AS Dividend Yield % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Gentian Diagnostics AS's Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Gentian Diagnostics AS's Dividend Yield % falls into.
Gentian Diagnostics AS Dividend Yield % Calculation
Dividend Yield measures how much a company pays out in dividends each year relative to its share price.
Gentian Diagnostics AS Recent Full-Year* Dividend History
Amount
Ex-date
Record Date
Pay Date
Type
Frequency
Forex Rate
NOK 0.600000
2026-05-06
2026-05-07
2026-05-18
Cash Dividend
annually
NOK:EUR 0.092017
* GuruFocus has an internal rule that if the most recent dividend payment frequency is at least 4 times a year, then the full year will be calculated according to the frequency of payment or the one-year time frame, whichever is stricter.
* GuruFocus converts dividend currency to local traded share price currency in order to calculate dividend yield. Please refer to the last column "Forex Rate" in the above table.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gentian Diagnostics AS (FRA:6FK) has a Dividend Yield % of 1.60% as of Jul. 12, 2026. Dividend yield is the ratio of company dividends to the share price. View historical data on Gentian Diagnostics AS and its competitors. This is 116% above median its historical median of 0.74. Over the past decade, Gentian Diagnostics AS's Dividend Yield % has ranged from 0.63 to 1.62. According to the industry distribution chart, Gentian Diagnostics AS ranks #191 out of 327 companies in the Medical Devices & Instruments industry, placing it in the top 58.4%.
Is Gentian Diagnostics AS's Dividend Yield % too high?
Gentian Diagnostics AS's current Dividend Yield % of 1.60% is 116% above median its 10-year median of 0.74. Over the past 10 years, this metric has ranged from a low of 0.63 to a high of 1.62. The Medical Devices & Instruments industry median Dividend Yield % is 1.92. Gentian Diagnostics AS's value of 1.60% is 16.7% below this industry median. Based on the distribution chart, Gentian Diagnostics AS ranks #191 out of 327 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Gentian Diagnostics AS has a GF Score™ of 73/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Gentian Diagnostics AS's Dividend Yield % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Gentian Diagnostics AS ranks #191 out of 327 companies for Dividend Yield %. This places Gentian Diagnostics AS in the lower half of its industry. The industry median Dividend Yield % is 1.92. Gentian Diagnostics AS's value of 1.60% is 16.7% below this benchmark. Historically, Gentian Diagnostics AS's own Dividend Yield % has ranged from 0.63 to 1.62 over the past decade. While the company's 10-year median is 0.74 vs. the industry median of 1.92, Gentian Diagnostics AS has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Dividend Yield % for a Medical Devices & Instruments company?
The median Dividend Yield % among Medical Devices & Instruments companies is 1.92, based on 327 companies in the industry. Companies in the top quartile (top 25%) have a Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Gentian Diagnostics AS's current Dividend Yield % of 1.60% is 16.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Dividend Yield % mean?
A high Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Dividend yield is the ratio of company dividends to the share price. View historical data on Gentian Diagnostics AS and its competitors. For the Medical Devices & Instruments industry, the median Dividend Yield % is 1.92 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Gentian Diagnostics AS's current Dividend Yield % is 1.60%, which is 116% above median its own 10-year median of 0.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gentian Diagnostics AS stock overvalued right now?
Based on GuruFocus' analysis, Gentian Diagnostics AS (FRA:6FK) is currently considered Significantly Undervalued. The stock's GF Value™ is €5.19, compared to a current price of €3.47 — trading 33.1% below its estimated fair value. The current Dividend Yield % is 1.60%, which is 116% above median its 10-year median of 0.74 and 16.7% below the Medical Devices & Instruments industry median of 1.92. Gentian Diagnostics AS's overall GF Score™ is 73/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Dividend Yield % calculated?
Dividend Yield % is calculated from a company's financial statements. For Gentian Diagnostics AS (FRA:6FK), the current Dividend Yield % is 1.60% as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Gentian Diagnostics AS (FRA:6FK) Overvalued in 2026?
Based on GuruFocus' analysis, Gentian Diagnostics AS stock appears to be undervalued.
The current stock price of €3.47 is trading 33.1% below its estimated GF Value™ of €5.19.
GuruFocus considers Gentian Diagnostics AS to be Significantly Undervalued.
Key valuation signals for FRA:6FK:
Dividend Yield %: 1.60% (116% above median its 10-year median of 0.74)
GF Value™: €5.19 vs. price of €3.47 (33.1% below fair value)
Industry Position: 16.7% below the Medical Devices & Instruments median (#191 of 327)
No single metric tells the full story. See the FRA:6FK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Gentian Diagnostics AS operates as a medical diagnostics company in Norway. It develops and produces in vitro diagnostic reagents (IVD) for medical diagnostics and research. Its portfolio and pipeline of reagents span areas such as inflammation, severe infections, kidney diseases, heart failure, and veterinary healthcare. The company's product portfolio includes the Gentian Cystatin C Immunoassay, the GCAL circulating calprotectin immunoassay (IVDR), the Gentian Retinol Binding Protein (RBP), and the Gentian Canine CRP, among others. Geographically, it generates a majority of its revenue from Europe, followed by Asia and the United States of America.
73GF Score
Get the complete analysis for FRA:6FK
Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:6FK has been successfully added to your 
